- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Furadonin - an antimicrobial drug, is a derivative of nitrofuran. It has a bactericidal and bacteriostatic effect in urinary tract infections, has a wide spectrum of action. Active against most strains of Escherichia coli, Staphylococcus spp., Streptococcus spp., Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Shigella sonnei, Proteus, Enterobacter spp.
Infectious and inflammatory diseases of the urinary tract, caused by microorganisms sensitive to the drug:
pyelitis; pyelonephritis; cystitis; urethritis;
Prevention of infections during urological operations or examination (cystoscopy, catheterization, etc.).
active substance: 100 mg nitrofurantoin
Nitrofurantoin is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
No customer reviews for the moment.
Dosage and Administration
Inside, drinking plenty of water, adults - 0.1-0.15 g, 3-4 times a day; children - at the rate of 5-8 mg / kg / day, the daily dose is divided into 4 doses. Higher doses for adults: single - 0.3 g, daily - 0.6 g.
For acute urinary tract infections, the duration of treatment is 7-10 days.
Preventive, anti-relapse treatment continues, depending on the nature of the disease, from 3 to 12 months. The daily dose in this case is 1-2 mg / kg.
Nausea, vomiting, allergic reactions (lupus-like syndrome, arthralgia, myalgia, anaphylaxis, chills, eosinophilia, rash), dizziness, headache, asthenia, nystagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, nonstagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, nonstagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, nonstagmus, drowsiness, interstitial changes in the lungs, broncho-obstructive syndrome, dysfunction, dysphagia, dysfunction , hepatitis, cholestatic syndrome, peripheral neuropathy, pancreatitis, pseudomembranous enterocolitis, rarely - abdominal pain, diarrhea.
- Hypersensitivity, chronic renal failure;
- heart failure II – III century;
- cirrhosis of the liver;
- chronic hepatitis;
- deficiency of glucose-6-phosphate dehydrogenase;
- acute porphyria;
- pregnancy and lactation;
- children's age up to 3 years.
The simultaneous use of nalidixic acid and antacids containing magnesium trisilikat reduces the antibacterial effect.
Incompatibility with fluoroquinolones.
Drugs that block tubular secretion, reduce the antibacterial effect (by reducing the concentration of nitrofurantoin in the urine) and increase the toxicity (increased concentration in the blood) of the drug.
Pregnancy and Lactation
The use of the drug during pregnancy and during breastfeeding is contraindicated.
Impact on the ability to drive vehicles and other mechanisms that require high concentration of attention
During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor speed (with the appearance of dizziness and drowsiness).
Treatment: the intake of large amounts of fluid leads to an increase in the excretion of the drug in the urine. Effective dialysis.
- Quantitative Bestimmung von Nitrofurantoin im Urin
- Quantitative Bestimmung von Nitrofurantoin in Körperflüssigkeiten durch HPLC mit Direktinjektion
- Polarographische Simultanbestimmung von Nitrofurantoin und Phenazopyridin in Tabletten
- Nitrofurantoin-induced antinuclear antibodies and panniculitis
- Absorption and disposition characteristics of nitrofurantoin in dogs
- Electrochemical behavior of nitrofurantoin and assay of its formulations
- Comparison of genomic damage caused by 5-nitrofurantoin in young and adult mice using the in vivo micronucleus assay
- Adaptive response of vibrio cholerae and escherichia coli to nitrofurantoin
- Comparison of the genetic activity of AF-2 and nitrofurantoin in log and stationary phase cells of saccharomyces cerevisiae
- Inhibition studies on the involvement of flavoprotein reductases in menadione- and nitrofurantoin-stimulated oxyradical production by hepatic microsomes of flounder (Platichthys flesus)
- Effect of pregnancy on nitrofurantoin disposition in mice
- Integrated approach to study the dehydration kinetics of nitrofurantoin monohydrate
- Nitrofurantoin–p-aminobenzoic acid cocrystal: Hydration stability and dissolution rate studies
- Laboratory studies with nitrofurantoin. Relationship between crystal size, urinary excretion in the rat and man, and emesis in dogs
- Urinary drug excretion in dogs during therapeutic doses of different nitrofurantoin dosage forms
- Detection of ampicillin contamination in nitrofurantoin preparations by high pressure liquid chromatography
- Inconsistencies in rationale underlying official USP dissolution rate specifications for nitrofurantoin
- pH-dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules
- Bioavailability of 14 nitrofurantoin products
- Nitrofurantoin solubility in aqueous urea solutions
- Effect of propantheline on nitrofurantoin absorption
- Determination of nitrofurantoin in urine by reduction at rotating platinum electrode